Skip to main content
main-content

Multiple sclerosis

25-10-2018 | Multiple sclerosis | News | Article

Medicinal cannabinoids show small antispastic and analgesic benefits for MS patients

The benefits of medicinal cannabinoids for the treatment of spasticity, pain and bladder dysfunction in patients with multiple sclerosis may be limited, suggests a systematic review and meta-analysis.

Source:

JAMA Network Open 2018; 1(6): e183485

JAMA Network Open 2018;1(6): e183484

13-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: Novel 3-in-1 MS-SMART trial fails on efficacy end-points but paves the way for multi-arm strategies

Jeremy Chataway reports on the latest findings from the MS-SMART trial that evaluated the efficacy of amiloride, fluoxetine and riluzole versus placebo in reducing disability in progressive multiple sclerosis as a way of speeding up phase II trial activity (2:57).

12-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: : ORATORIO extension-phase trial findings show sustained reduction in MS disability progression with ocrelizumab

Jerry Wolinksy summarises his findings from the open-label extension period of the phase III ORATORIO trial looking at sustained disability progression with ocrelizumab in patients with primary progressive multiple sclerosis (8:20).

12-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: Sensitivity for predicting a second MS episode increased with McDonald 2017 criteria

Roos M van der Vuurst de Vries discusses her McDonald 2017 criteria findings, which provide further support of improved sensitivity for diagnosing clinically definite multiple sclerosis in patients with clinically isolated syndrome (5:05).

12-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: Real-world data support early treatment initiation in relapsing-remitting MS patients

Pietro Iaffaldano shares his real-world findings from the Big Multiple Sclerosis Data Network showing an optimal time to treatment initiation of 6 months in patients with relapsing-remitting multiple sclerosis (1:51).

12-10-2018 | Multiple sclerosis | Video

ECTRIMS 2018: McDonald 2017 criteria allows for earlier MS diagnosis than McDonald 2010 in patients with clinically isolated syndrome

Wallace Brownlee presents his study showing that the revised McDonald 2017 criteria are more sensitive than the McDonald 2010 criteria, albeit with a modest reduction in specificity, for diagnosing multiple sclerosis in patients with typical clinically isolated syndrome characteristics (3:49).

image credits